Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Apellis Pharmaceuticals (APLS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
10:35am, Thursday, 30'th Oct 2025
While the top- and bottom-line numbers for Apellis Pharmaceuticals (APLS) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its k
Apellis Pharmaceuticals, Inc. (APLS) Q3 Earnings and Revenues Top Estimates
09:16am, Thursday, 30'th Oct 2025
Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to a loss of $0.46 per share a year ago
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
07:05am, Thursday, 30'th Oct 2025
WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its third quarter 2025 financial results and business highlights.
Apellis Pharmaceuticals, Inc. (APLS) Reports Next Week: Wall Street Expects Earnings Growth
11:05am, Thursday, 23'rd Oct 2025
Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced new data from the open-label period of the Phase 3 VALIANT study that reinforce the robus
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
07:00am, Thursday, 16'th Oct 2025
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced t
Apellis Pharmaceuticals: Maintaining "Buy" Rating With Continued EMPAVELI Expansions Beyond PNH And C3G-Disorders
04:34pm, Tuesday, 30'th Sep 2025
Apellis Pharmaceuticals maintains a strong "Buy" rating for me, driven by robust SYFOVRE sales and recent EMPAVELI FDA approvals for rare kidney diseases. APLS is expanding SYFOVRE's potential with a
Apellis Pharmaceuticals, Inc. (APLS) Presents At Baird Global Healthcare Conference (Transcript)
12:55pm, Tuesday, 09'th Sep 2025
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Baird Global Healthcare Conference September 9, 2025 10:15 AM EDT Company Participants Cedric Francois - Co-Founder, President, CEO & Director Timothy Sull
Apellis Pharmaceuticals, Inc. (APLS) Presents At Cantor Global Healthcare Conference 2025 (Transcript)
11:20am, Thursday, 04'th Sep 2025
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Cantor Global Healthcare Conference 2025 September 4, 2025 8:35 AM EDT Company Participants Cedric Francois - Co-Founder, President, CEO & Director Timothy
Apellis Pharmaceuticals, Inc. (APLS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
11:24am, Wednesday, 03'rd Sep 2025
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 8:45 AM EDT Company Participants Timothy Sullivan - CFO & Treasurer David Acheson - Ex
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 27'th Aug 2025
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor con
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval
12:12pm, Thursday, 14'th Aug 2025
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval
Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript
04:23am, Saturday, 02'nd Aug 2025
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Caroline R. Baumal - Chief Medical Officer Cedric Francois - Co-Founder, Pre
Apellis Pharmaceuticals: The Picture Becomes Clearer
02:29pm, Friday, 01'st Aug 2025
Apellis Pharmaceuticals has made pipeline progress and strengthened its balance sheet since I looked at this biopharma name earlier this year, warranting a fresh look at the stock. Recent approvals fo
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say
10:31am, Thursday, 31'st Jul 2025
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall
